Appendix
IPROVE Advisory Board
Last name | First name | Organisation |
Cavaleri | Marco | European Medicines Agency |
Fritzell | Bernard | Consultant |
Lambert | Paul-Henri | University of Geneva |
Salisbury | David | Consultant |
IPROVE Affiliated Members
Last name | First name | Organisation |
Autran | Brigitte | CoReVac (France) |
Bousselet | Alice | AVIESAN (France) |
Drury | Gerogina | Medical Research Council (United Kingdom) |
Gabriele | Lucia | Istituto Superiore di Sanità (Italy) |
Hoitink | Carla | Intravacc (Netherlands) |
IPROVE List of Stakeholder Consultation Workshops
Topic | Date | Place |
Vaccine SME needs | 15 May 2014 | Brussels |
Vaccine communication and hesitancy | 28 October 2014 | Brussels |
Training needs | 28 October 2014 | Brussels |
Vaccine R&D | 12-13 March 2015 | Brussels |
Manufacturing and quality control | 12 March 2015 | Brussels |
Infrastructures | 13 March 2015 | Brussels |
Therapeutic vaccines | 26 May 2015 | Brussels |
Table of figures
Figure 1: Number of Vaccine Clinical Trials 2000 – 2009; Source: clinicaltrials.gov
Figure 2: Number of Vaccines Clinical Trials 2010 – 2015; Source: clinicaltrials.gov
Figure 3: Safety and efficacy of replicating and non replicating vaccine approaches(http://www.iavireport.org/)
Figure 4: Therapeutic Vaccines Trials conducted between 2010 and 2015; Source: clinicaltrials.gov
Figure 5: VC targeting vaccines; Source: courtesy of Dr. Michael Watson, Sanofi Pasteur
Figure 6: PharmaDeals – Vaccine deal trends 2000 – 2015